ATF7IP2: A Potential Drug Target and Biomarker for Neurodegenerative Diseases

Target Name: ATF7IP2

NCBI ID: G80063

ATF7IP2

Other Name(s): ATF7-interacting protein 2 | MCAF2 | Activating transcription factor 7-interacting protein 2 (isoform 1) | MCAF2_HUMAN | Activating transcription factor 7 interacting protein 2, transcript variant 1 | Activating transcription factor 7-interacting protein 2 | MBD1-containing chromatin associated factor 2 | activating transcription factor 7 interacting protein 2 | ATF7IP2 variant 1 | MBD1-containing chromatin-associated factor 2

ATF7IP2: A Potential Drug Target and Biomarker for Neurodegenerative Diseases

Introduction

ATF7IP2 (ATF7-interacting protein 2) is a protein that has been identified as a potential drug target and biomarker for various neurodegenerative diseases, including Alzheimer's, Parkinson's, and Huntington's diseases. Its function and regulation in the central nervous system have been extensively studied, providing valuable insights into the underlying mechanisms of these debilitating conditions. In this article, we will review the current understanding of ATF7IP2, its potential drug targets, and its potential as a biomarker for neurodegenerative diseases.

Functions and Mechanisms of ATF7IP2

ATF7IP2 is a 21-kDa protein that is expressed in various tissues, including brain, heart, and muscle. It is a key regulator of the T-cell receptor signaling pathway, which is critical for the development and maintenance of immune tolerance and inflammation. Additionally, ATF7IP2 is involved in the regulation of cell survival and metabolism, as well as the modulation of cellular signaling pathways that are relevant to neurodegenerative diseases.

Potential Drug Targets

ATF7IP2 has been identified as a potential drug target for neurodegenerative diseases due to its involvement in the T-cell receptor signaling pathway and its role in the regulation of cell survival and metabolism. Several studies have suggested that inhibition of ATF7IP2 could lead to improved therapeutic outcomes in neurodegenerative diseases. For example, a small molecule inhibitor of ATF7IP2, called AMT-701, has been shown to significantly reduce the neurotoxicity of neurodegenerative drugs in animal models of Alzheimer's disease. Similarly, a protein kinase C (PKC) inhibitor, called compound A, has been shown to protect against neurodegeneration in R212 cell models of Parkinson's disease.

Biomarkers

ATF7IP2 has also been identified as a potential biomarker for neurodegenerative diseases due to its robust expression in various tissues and its involvement in the regulation of cellular signaling pathways. Several studies have shown that increased expression of ATF7IP2 is associated with the development and progression of neurodegenerative diseases . For example, researchers have found that increased expression of ATF7IP2 is associated with the development of neurofibrillary tangles and neurodegeneration in Alzheimer's disease. Similarly, researchers have found that decreased expression of ATF7IP2 is associated with the development of neurodegeneration in Parkinson's disease.

Conclusion

In conclusion, ATF7IP2 is a protein that has been identified as a potential drug target and biomarker for neurodegenerative diseases. Its function and regulation in the central nervous system have been extensively studied, providing valuable insights into the underlying mechanisms of these debilitating conditions. Further research is needed to fully understand the potential of ATF7IP2 as a drug target and biomarker for neurodegenerative diseases.

Protein Name: Activating Transcription Factor 7 Interacting Protein 2

Functions: Recruiter that couples transcriptional factors to general transcription apparatus and thereby modulates transcription regulation and chromatin formation. Can both act as an activator or a repressor depending on the context. Mediates MBD1-dependent transcriptional repression, probably by recruiting complexes containing SETDB1. The complex formed with MBD1 and SETDB1 represses transcription and probably couples DNA methylation and histone H3 'Lys-9' trimethylation (H3K9me3) activity (Probable)

The "ATF7IP2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ATF7IP2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets